DAWN (Day One Biopharmaceuticals) EBIT: $-127.8 Mil (TTM As of Dec. 2025)

What is Day One Biopharmaceuticals EBIT?

Day One Biopharmaceuticals DAWN 12 EBIT is $-127.8 Mil as of Dec. 2025. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

Day One Biopharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $-27.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-127.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Day One Biopharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2025 was -363.76%. Day One Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2,399.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Day One Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -7.15%.

Day One Biopharmaceuticals (NAS:DAWN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Day One Biopharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-109.832 * ( 1 - 8.5% )	/	( (29.68	+	25.574)	/ 2 )
=	-100.49628	/	27.627
=	-363.76 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	513.78	-	50.595	-	( 451.58	-	max(0, 56.466	-	489.971	+	451.58	))
=	29.68

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	507.827	-	57.676	-	( 441.113	-	max(0, 60.522	-	485.099	+	441.113	))
=	25.574

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Day One Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-109.832	/	( ( (4.677 + max(-17.914, 0))	+	(4.478 + max(-16.362, 0)) )	/	2 )
=	-109.832	/	( ( 4.677	+	4.478 )	/	2 )
=	-109.832	/	4.5775
=	-2,399.39 %

where Working Capital is:

	Working Capital		(Q: Sep. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(16.697	+	7.061	+	14.633)	-	(50.595	+	2.317	+	3.393)
=	-17.914

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(26.735	+	6.326	+	10.925)	-	(57.676	+	2	+	0.672)
=	-16.362

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Day One Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-127.75	/	1786.465
	=	-7.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Day One Biopharmaceuticals EBIT Related Terms

Day One Biopharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Day One Biopharmaceuticals's EBIT can be seen below:

Day One Biopharmaceuticals EBIT Chart

Day One Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-72.74

-146.91

-206.06

-217.27

-127.75

Day One Biopharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
EBIT	Get a 7-Day Free Trial															-65.33	-41.07	-34.97	-24.25	-27.46

DAWN vs TYRA, DFTX, MLYS: EBIT Comparison

For the Biotechnology subindustry, Day One Biopharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Day One Biopharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's EV-to-EBIT falls into.

Save Embed

12GF Score

Day One Biopharmaceuticals Inc DAWN

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Day One Biopharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-127.8 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-127.8 Mil mean?

Day One Biopharmaceuticals (DAWN) has a EBIT of $-127.8 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Day One Biopharmaceuticals.

Is Day One Biopharmaceuticals' EBIT too high?

Day One Biopharmaceuticals' current EBIT is $-127.8 Mil. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Day One Biopharmaceuticals' EBIT compare to TYRA and DFTX?

Day One Biopharmaceuticals' EBIT of $-127.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Day One Biopharmaceuticals. Day One Biopharmaceuticals's current EBIT is $-127.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Day One Biopharmaceuticals stock overvalued right now?

Day One Biopharmaceuticals (DAWN) has a current EBIT of $-127.8 Mil. The current EBIT is $-127.8 Mil. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current EBIT is $-127.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Day One Biopharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies TYRA DFTX MLYS ADPT SRPT ZYME RARE AUPH OCUL TRVI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL ALNY ONC XKRX:068270 INSM

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005

Website https://www.dayonebio.com

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.

12GF Score

Get the complete analysis for DAWN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53

Price

View DAWN Analysis

See EBIT data for all stocks →